Tanja Skyttä

Medicine & Life Sciences

1. Radiotherapy 100%
2. Unilateral Breast Neoplasms 74%
3. Adjuvant Radiotherapy 70%
4. Breast Neoplasms 59%
5. Radiation 51%
6. Echocardiography 39%
7. Breast 35%
8. Melanoma 31%
9. Thoracic Wall 27%
10. Sternum 27%
11. Lymph Nodes 26%
12. Phase II Clinical Trials 25%
13. Vascular Endothelial Growth Factor Receptor-1 24%
14. Heart 24%
15. Right Ventricular Function 23%
16. Vascular Endothelial Growth Factor Receptor-2 23%
17. Aromatase Inhibitors 23%
18. Melphalan 23%
19. Troponin T 22%
20. Clinical Trials, Phase I 22%
21. Spine 21%
22. Bevacizumab 21%
23. Patient Reported Outcome Measures 20%
24. Ribs 20%
25. Finland 20%
26. Lymphocyte Activation 20%
27. Inhalation 17%
28. Cardiotoxicity 17%
29. Direction compound 15%
30. Observer Variation 14%
31. Perfusion 14%
32. Extremities 13%
33. Heart Failure 13%
34. Down-Regulation 13%
35. Therapeutics 12%
36. Electrocardiography 10%
37. Neoplasms 10%
38. Biomarkers 10%
39. Macrophages 9%
40. Survival 9%
41. Drug Therapy 8%
42. Left Ventricular Dysfunction 8%
43. Organs at Risk 8%
44. Lung 6%
45. Progression-Free Survival 6%
46. Posture 6%
47. Patient Rights 5%
48. Serum 5%
49. Heart Diseases 5%
50. Mortality 5%